Hedera Dx was created in 2021 with the mission to give access to liquid biopsy technologies to patients at risk of or already suffering from cancer.
Hedera Dx has raised €29M across 2 funding rounds from 10 investors, most recently a Series A round in May 2025. Based in Lausanne, Switzerland; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-05-27 | Series A | €15M | Eyrir Venture Management,Helsana HealthInvest,Inventure,Tesi,Top Harvest Capital,Vsquared Ventures | View deal → |
| 2022-09-21 | Other | €14M | Air Street Capital,Adam Ghobarah,Amino Collective,GRIDS Capital,Inventure | View deal → |
